279,827 Shares in Abbott Laboratories $ABT Bought by ABN AMRO Bank N.V.

ABN AMRO Bank N.V. acquired a new stake in shares of Abbott Laboratories (NYSE:ABT) in the third quarter, Holdings Channel.com reports. The institutional investor acquired 279,827 shares of the healthcare product maker’s stock, valued at approximately $37,142,000.

Other institutional investors and hedge funds also recently made changes to their positions in the company. IMG Wealth Management Inc. lifted its position in shares of Abbott Laboratories by 759.1% during the second quarter. IMG Wealth Management Inc. now owns 189 shares of the healthcare product maker’s stock valued at $26,000 after purchasing an additional 167 shares in the last quarter. Cloud Capital Management LLC purchased a new position in shares of Abbott Laboratories in the 3rd quarter worth approximately $29,000. Guerra Advisors Inc bought a new position in shares of Abbott Laboratories in the third quarter valued at approximately $31,000. Anfield Capital Management LLC increased its position in shares of Abbott Laboratories by 81.3% during the second quarter. Anfield Capital Management LLC now owns 232 shares of the healthcare product maker’s stock valued at $32,000 after acquiring an additional 104 shares during the last quarter. Finally, Delos Wealth Advisors LLC bought a new stake in Abbott Laboratories during the second quarter worth $32,000. Institutional investors and hedge funds own 75.18% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on ABT. Wells Fargo & Company raised their target price on Abbott Laboratories from $142.00 to $146.00 and gave the company an “overweight” rating in a research report on Thursday, October 16th. Leerink Partners decreased their price objective on shares of Abbott Laboratories from $136.00 to $119.00 and set a “market perform” rating for the company in a report on Friday, January 30th. Piper Sandler dropped their target price on shares of Abbott Laboratories from $150.00 to $135.00 and set an “overweight” rating on the stock in a research note on Friday, January 23rd. William Blair upgraded shares of Abbott Laboratories to a “strong-buy” rating in a research note on Thursday, November 20th. Finally, Barclays lowered their price target on shares of Abbott Laboratories from $169.00 to $142.00 and set an “overweight” rating on the stock in a report on Monday. Two equities research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $137.05.

Abbott Laboratories Trading Down 0.8%

Shares of ABT opened at $108.18 on Thursday. The company has a debt-to-equity ratio of 0.23, a current ratio of 1.70 and a quick ratio of 1.24. Abbott Laboratories has a 1-year low of $105.27 and a 1-year high of $141.23. The company has a market capitalization of $188.11 billion, a P/E ratio of 29.08, a P/E/G ratio of 1.73 and a beta of 0.75. The firm’s 50 day simple moving average is $121.62 and its 200 day simple moving average is $127.11.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings results on Thursday, January 22nd. The healthcare product maker reported $1.50 earnings per share (EPS) for the quarter, hitting the consensus estimate of $1.50. The firm had revenue of $11.46 billion during the quarter, compared to analyst estimates of $11.80 billion. Abbott Laboratories had a return on equity of 17.94% and a net margin of 14.72%.The company’s revenue was up 4.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.34 earnings per share. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. Sell-side analysts forecast that Abbott Laboratories will post 5.14 earnings per share for the current fiscal year.

Abbott Laboratories Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, February 13th. Stockholders of record on Thursday, January 15th will be paid a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.3%. This is a boost from Abbott Laboratories’s previous quarterly dividend of $0.59. The ex-dividend date of this dividend is Thursday, January 15th. Abbott Laboratories’s payout ratio is currently 67.74%.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.